Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy

NCT00244920 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT00244920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00244920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2002
Completion date
June 30, 2007
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer